Share chart Zai Lab Limited
Extended chart
Simple chart
About Zai Lab Limited
Zai Lab Limited, биофармацевтическая компания, занимается открытием или лицензированием, разработкой и коммерциализацией патентованных терапевтических средств, которые удовлетворяют медицинские потребности в области онкологии, аутоиммунных и инфекционных заболеваний в Китае. Компания предлагает нирапариб, низкомолекулярный пероральный ингибитор поли-АДФ-рибозы-полимеразы 1> F2 для лечения множественных солидных опухолей, включая рак яичников и другие типы рака легких; и Optune, противоопухолевое средство для лечения мультиформной глиобластомы. more detailsIPO date | 2017-09-20 |
---|---|
ISIN | US98887Q1040 |
Industry | Biotechnology |
Sector | Health Care |
Валюта | usd |
Валюта отчета | usd |
Див.доход ао | 0 |
Сайт | http://www.zailaboratory.com |
Цена ао | 35.4 |
Change price per day: | 0% (35.4) |
---|---|
Change price per week: | -6.87% (38.01) |
Change price per month: | +7.44% (32.95) |
Change price per 3 month: | +31.65% (26.89) |
Change price per half year: | +56.64% (22.6) |
Change price per year: | +118.65% (16.19) |
Change price per 3 year: | -18.56% (43.47) |
Change price per 5 year: | -30.53% (50.96) |
Change price per year to date: | +33.38% (26.54) |
|
Underestimation
|
Efficiency
|
|||||||||||||||||||||||||||||||||||||
Dividends
|
Debt
|
Growth impulse
|
Institutions | Volume | Share, % |
---|---|---|
Wellington Management Group, LLP | 5336457 | 5.38 |
Capital World Investors | 5218843 | 5.26 |
Janus Henderson Group PLC | 4040282 | 4.07 |
Price (T.Rowe) Associates Inc | 2704455 | 2.73 |
Woodline Partners LP | 2018527 | 2.03 |
Invesco Ltd. | 1893529 | 1.91 |
Viking Global Investors, L.P. | 1869283 | 1.88 |
Segantii Capital Management Ltd | 1687569 | 1.7 |
BAMCO Inc. | 1490874 | 1.5 |
FMR, LLC | 1236927 | 1.25 |
ETF | Share, % | Profitability for 1 year, % | Dividends, % |
---|---|---|---|
Global X China Biotech Innovation ETF | 6.23 | -20.1 | |
Amplify Treatments Testing and Advancements ETF | 3.44 | 10.31 | 1.06 |
Virtus LifeSci Biotech Products ETF | 1.55193 | 36.79 | 0.13953 |
Invesco Golden Dragon China ETF | 0.70888 | 0.1125 | 1.92373 |
AltShares Event-Driven ETF | 0.41039 | 9.61 | 1.21959 |
Fidelity Women's Leadership ETF | 0.2544 | 26.3 | 1.1649 |
ProShares UltraShort Nasdaq Biotechnology | 0.24 | -40.36 | 1.76 |
Future Tech ETF | 0.10907 | 426.34 | 0.8416 |
Principal Healthcare Innovators ETF | 0.10907 | 618.5 | 0.8416 |
Invesco Nasdaq Biotechnology ETF | 0.10444 | 28.58 | 0.8565 |
ProShares Ultra Nasdaq Biotechnology | 0.07258 | 51.7 | 0.85651 |
WisdomTree Emerging Markets Efficient Core Fund | 0.02082 | 17.03 | 3.08497 |
SPDR Portfolio MSCI Global Stock Market ETF | 0.00429 | 17.99 | 2.19607 |
Dimensional Emerging Markets Core Equity 2 ETF | 0.00358 | 15.96 | 3.34087 |
0.95 | 85.63 | 1.38 |
Head | Job title | Payment | Year of birth |
---|---|---|---|
Dr. Ning Xu M.D. | Executive VP & Head of Clinical Operations | N/A | 1965 (60 years) |
Dr. Ying Du Ph.D. | Founder, Chairperson & CEO | 1.67M | 1966 (59 years) |
Dr. Peter Huang Ph.D. | Chief Scientific Officer | N/A | |
Mr. Joshua L. Smiley | President & COO | 647.11k | 1970 (55 years) |
Dr. Rafael G. Amado M.D. | President and Head of Global Research & Development | 477k | 1964 (61 year) |
Dr. Yajing Chen Ph.D. | Chief Financial Officer | N/A | 1968 (57 years) |
Mr. Frazor Titus Edmondson III, J.D. | Chief Legal Officer & Joint Corporate Secretary | 829k | 1966 (59 years) |
Ms. Christine Chiou | Senior VP & Head of Investor Relations | N/A | |
Dr. Jonathan J. Wang MBA, Ph.D. | Chief Business Officer | 1982 (43 years) | |
Dr. James Yan DABT, M.D., Ph.D. | Chief Operating Officer of R&D | 1964 (61 year) |
Address: China, Shanghai , Building 1 Jinchuang Plaza - open in Google maps, open in Yandex maps
Website: http://www.zailaboratory.com
Website: http://www.zailaboratory.com